12:00 AM
 | 
Jun 08, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Biferonex interferon beta-1a regulatory update

Bioton withdrew an MAA for Biferonex interferon beta-1a to treat relapsing-remitting multiple sclerosis (RRMS). The company had initially requested re-examination of a negative opinion...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >